Biotest announces performance in line with forecasts for 2023

Biotest AG achieved a significant improvement in its EBIT for the 2023 financial year, reaching 143 million euros compared to -16.6 million euros the previous year. This result falls within the announced forecast range of 130 to 170 million euros.

The company also recorded a significant increase in revenue, from €516.1 million in 2022 to €684 million in 2023. This growth includes revenue from an agreement with Grifols on disclosure technology and development services, as well as one-off effects linked to changes in the scope of consolidation.

Biotest plans to propose at the next Annual General Meeting the distribution of a preferential dividend for 2023 and the subsequent payment of the preferential dividend for 2022 to preferential shareholders, after a year without payment of dividends due to accumulated losses.

The final results for the 2023 financial year will be published on March 28, 2024, in accordance with IFRS standards. With these performances, Biotest confirms its positive trajectory and its growth prospects.